The underlying philosophy of the Neuropathology Core is the belief that validation of diagnosis is critical to clinical research into neurodegenerative diseases and that tissue- and other biospecimen-based studies are a vital complement to in vitro studies of the biologic processes underlying these diseases. From these two pillars to the clinical and scientific community, the Core is able to make a contribution to the amelioration of suffering associated with AD and related disorders. The Core therefore supports the overall mission of the MADRC through the collection, characterization, storage and distribution of brain tissue and other biospecimens (CSF, plasma, DNA, RNA, etc) from subjects who have been well-characterized clinically. Samples from the Core have contributed to significant advances in our understanding of the biologic processes that characterize neurodegenerative diseases, both at early and later stages. The Core will serve to catalyze research into AD through collection, characterization and distribution of samples to individual investigators, larger consortia and collaborative groups and through data sharing with NACC (Aims 1-4). There are components of the Core's activities which are innovative, focused on developing novel tissue handling methods for high resolution microscopy which is important for understanding of early events in AD, on developing novel methods for imaging sharing and analysis and on harnessing opportunities provided by large epidemiologic studies to gather samples from control and early stage subjects (Aims 5-7). Finally, there is an educational component of the Core: training neuropathologists to be expert in diagnosis of neurodegenerative diseases and in the operations of tissue repositories in support of research;and teaching other health professionals about the importance of autopsy and tissue donation for research (Aims 8 &9). The Core is integrated into all Center activities with active interactions with Administrative, Clinical and Outreach Cores regarding autopsy permission and education, with the Data Core regarding data storage and communication with NACC, and with the projects. Projects 2 and 3 both depend on neuropathological samples from the Core, and our routine evaluation of brains includes attention to the white matter, which complements Project 1's Connectome studies. We also support the local research community and national initiatives, with 309 requests for materials over the past 4 years (including >3600 frozen tissue samples and >17,000 unstained section). Thus, there is an ever-increasing role for the activities of the Core in contributing to research in AD and other dementing illnesses.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG005134-31
Application #
8676353
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
31
Fiscal Year
2014
Total Cost
$228,539
Indirect Cost
$97,195
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Viswanathan, Anand; Greenberg, Steven M; Scheltens, Philip (2016) Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment. Stroke 47:577-80
Dhilla Albers, Alefiya; Asafu-Adjei, Josephine; Delaney, Mary K et al. (2016) Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. Ann Neurol 80:846-857
Day, Gregory S; Musiek, Erik S; Roe, Catherine M et al. (2016) Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA Neurol 73:1125-32
Ronquillo, Jay Geronimo; Baer, Merritt Rachel; Lester, William T (2016) Sex-specific patterns and differences in dementia and Alzheimer's disease using informatics approaches. J Women Aging 28:403-11
Herold, C; Hooli, B V; Mullin, K et al. (2016) Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry 21:1608-1612
Serrano-Pozo, Alberto; Betensky, Rebecca A; Frosch, Matthew P et al. (2016) Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. Am J Pathol 186:375-84
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-20
Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90
Grogg, Kira S; Toole, Terrence; Ouyang, Jinsong et al. (2016) National Electrical Manufacturers Association and Clinical Evaluation of a Novel Brain PET/CT Scanner. J Nucl Med 57:646-52
Rentz, Dorene M; Dekhtyar, Maria; Sherman, Julia et al. (2016) The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis 3:8-12

Showing the most recent 10 out of 717 publications